BI
JNCE

BVF Inc’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

BVF Inc’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-126,797
Closed -$861K – 85
2022
Q1 		$861K Buy
+126,797
New +$904K 0.03% 79

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

BVF Inc's JNCE Position: Q2 2022 in Review

BVF Inc sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2022, closing a stake of 126,797 shares — an estimated $861K sold.

BVF Inc first reported a position in JNCE in Q1 2022 and held it in 1 quarter. The position peaked at $861K in Q1 2022. 102 funds tracked by Wall St. Rank hold JNCE as of Q2 2022.

  • BVF Inc reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • BVF Inc sold 126,797 Jounce Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $861K.
  • BVF Inc first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • BVF Inc's Jounce Therapeutics, Inc. Common Stock position peaked at $861K in Q1 2022.
  • 102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2022.

Based on BVF Inc's 13F filing for Q2 2022, filed 15 Aug 2022.